Skip to main content

Advertisement

Table 2 The clinicopathologic characteristics and genetic profiles for patients with ALK rearrangement and c-Met overexpression

From: Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Patients P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15
Age (y) < 60 < 60 < 60 < 60 < 60 < 60 < 60 < 60 < 60 > 60 > 60 < 60 < 60 > 60 < 60
Histology ADC ADC ADC ADC ADC ADC ADC ADC ADC ADC ADC ADC ADC ADC ADC
Stage IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV
Smoking 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
PS 0 1 1 1 1 1 1 1 1 1 1 0 1 1 1
C-Met IHC 50%+++, 30%+ 70%+++,10%++,20%+ 60%+++, 40%++ 70%+++,30%+ 100%+++ 50%+++, 50%++ 60%+++, 40%++ 60%+++, 40%++ 100%+++ 50%+++
50%++
90%+++ 90%+++ 90%+++ 90%+++ 90%+++
FISH ND ND ND ND ND ND ND
ALK IHC + ND + ND ND ND + + ND + + + + + +
FISH ND 60% ND 29% 20% 74% ND ND 60% ND ND ND ND ND ND
Race-PCR ND ND ND ND V3 ND V1 ND ND ND ND V1 ND ND ND
EGFR WT WT WT WT WT WT WT WT WT WT WT WT WT WT 19 del
KRAS WT WT WT WT WT WT WT WT WT WT WT WT WT WT WT
  1. Abbreviations: F female, M male, ADC adenocarcinoma, PR partial response, m months, ALK anaplastic lymphoma kinase, c-Met cellular-mesenchymal-epithelial transition, EGFR epidermal growth factor receptor, KRAS kirsten rat sarcoma viral oncogene homolog, IHC Ventana immunohistochemistry, FISH fluorescent in situ hybridization, RACE PCR rapid amplification of cDNA ends coupled polymerase chain reaction, ND not done, V variant, 19 del exon 19 deletion